New Insights: Psilocybin and Post-Lyme Health
Premier Integrative & Cognitive Medical Institute
Chronic symptoms following Lyme disease, such as fatigue, cognitive fog, pain, and mood disturbances, can persist even after standard antibiotic treatment, leaving patients searching for relief. A recent pilot study offers a new avenue of hope: psilocybin-assisted therapy.
The Study at a Glance
Published in Scientific Reports (2026), the study led by Garcia-Romeu and colleagues enrolled 20 participants with post-treatment Lyme disease (PTLD). Each received two guided psilocybin sessions over eight weeks, beginning with a 15 mg dose and followed by a second session of 15–25 mg.
Psychological support was provided before, during, and after each session to ensure safety and proper integration.
Key Findings
Participants experienced significant improvements across multiple areas:
- Overall symptoms and quality of life: Marked reduction in PTLD-related fatigue, pain, and cognitive difficulties
- Mood and emotional well-being: Decreased anxiety and depressive symptoms
- Sleep and energy: Improved restorative sleep and more consistent energy levels
- Pain management: Reductions in chronic pain intensity
These benefits were not short-lived. Most improvements persisted for up to six months.
Safety and Tolerability
No serious adverse events were reported. The most common mild effects included:
- Temporary increases in blood pressure
- Headaches
- Rapid heartbeat
All effects were manageable within a clinical setting.
Why This Matters
This study highlights psilocybin’s potential to address persistent, treatment-resistant symptoms in PTLD by temporarily increasing neural flexibility. This process may help the brain reorganize patterns contributing to fatigue, pain, and mood challenges.
While preliminary, these findings suggest psilocybin-assisted therapy may become a meaningful option for chronic post-infectious conditions.
Looking Ahead
Ongoing research will continue refining how psilocybin therapy can best support patients, including personalized dosing and structured integration strategies.
For individuals experiencing persistent post-Lyme symptoms, this research reinforces the importance of exploring innovative, evidence-based care within a medically supervised environment.
Read the Study: Garcia-Romeu, A., Naudé, G.P., Rebman, A.W. et al. Pilot study of psilocybin in patients with post-treatment Lyme disease. Sci Rep 16, 7497 (2026). https://doi.org/10.1038/s41598-026-38091-9